Steve Brozak is the Managing Partner and President of WBB Securities, LLC. In 2013, Dr. Brozak was selected as a top analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards. He also was named to The Wall Street Journal’s “Best on the Street” list in the category of medical equipment and supplies. Earlier, Dr. Brozak worked in finance at Alex. Brown & Sons, Cowen & Company, Dean Witter and Salomon Brothers. Dr. Brozak has written for Nature, The British Medical Journal and Brain Stimulation. He is also a contributor to Forbes and ABC News. He received a B.A. degree and an MBA from Columbia University and a Doctorate in Medical Humanities — DMH — from Drew University. He served in the United States Marine Corps, retiring as a lieutenant colonel.
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
October 20, 2024
Two Deeply Discounted Biotechs Offer Innovative COVID Treatments
November 12, 2023
High Cost of Funds Presents Critical Challenge for Biotech Sector
March 30, 2023
Biotechs That Battle Infection Meet a Growing Need
March 18, 2022
Early-Stage Anti-Inflammatory Drugs May Provide Breakthrough Treatments
September 30, 2021
Looking Toward the Downtrodden Infectious Space for Opportunities
March 20, 2020
Scrutiny of Pharmacy Benefit Managers Resulting in Visibility of Drug Prices
March 27, 2019
Critical Demand for Innovation in Pharma and Biotech
August 12, 2016
Consolidation in Medical Devices Sector Replacing R&D and Product Launches
June 20, 2014
A Health Care Convergence of Biotech, Pharma and Medical Devices
February 21, 2014
